SNDX Stock Overview
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Syndax Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$20.57 |
52 Week High | US$25.34 |
52 Week Low | US$11.22 |
Beta | 0.98 |
1 Month Change | -4.06% |
3 Month Change | 1.73% |
1 Year Change | 0.93% |
3 Year Change | 28.97% |
5 Year Change | 198.12% |
Change since IPO | 71.27% |
Recent News & Updates
Recent updates
Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08Is Syndax Pharmaceuticals (NASDAQ:SNDX) Weighed On By Its Debt Load?
Jun 11Shareholders Would Not Be Objecting To Syndax Pharmaceuticals, Inc.'s (NASDAQ:SNDX) CEO Compensation And Here's Why
May 07The Syndax Pharmaceuticals (NASDAQ:SNDX) Share Price Has Gained 150%, So Why Not Pay It Some Attention?
Mar 15What Type Of Shareholders Own The Most Number of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares?
Jan 19Shareholder Returns
SNDX | US Biotechs | US Market | |
---|---|---|---|
7D | 0.4% | 0.4% | 1.0% |
1Y | 0.9% | 0.9% | 21.9% |
Return vs Industry: SNDX matched the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: SNDX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
SNDX volatility | |
---|---|
SNDX Average Weekly Movement | 6.8% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SNDX has not had significant price volatility in the past 3 months.
Volatility Over Time: SNDX's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 184 | Michael Metzger | www.syndax.com |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat.
Syndax Pharmaceuticals, Inc. Fundamentals Summary
SNDX fundamental statistics | |
---|---|
Market cap | US$1.75b |
Earnings (TTM) | -US$209.36m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.3x
P/E RatioIs SNDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SNDX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$209.36m |
Earnings | -US$209.36m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.46 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did SNDX perform over the long term?
See historical performance and comparison